BESNOTAMIG
UNII 9E5QRF8H7K
Substance Identification & Data
This profile provides standardized clinical and technical data for Besnotamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 9E5QRF8H7K.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3082353-64-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
9E5QRF8H7K
3082353-64-5
N/A
Detailed Substance Profile
Preferred Name
BESNOTAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
INN ID
14184
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Besnotamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Besnotamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Besnotamig
Common Names & Synonyms
Immunoglobulin G4, bispecific, [404-cysteine,417-glutamine,482-proline,608-cysteine,620-tryptophan,de-C-terminal lysine], anti-(human CD20 antigen) (human-Mus musculus monoclonal rituximab (IDEC-C2B8) Fab fragment) fusion protein with peptide linker ((GGGGS)2) fusion protein with immunoglobulin anti-(human CD3 antigen ε-chain)(human-Mus musculus monoclonal W3311-2.306.4-z1 heavy chain variable region) fusion protein with T cell receptor β-chain (human C-region fragment) fusion protein with immunoglobulin G4 (human γ4-chain C-region-C-terminal fragment), (480→227′),(483→230′),(608→350′)-tris(disulfide) with immunoglobulin G4 [229′-proline,350′-cysteine,367′-sreine,369′-alanine,408′-valine,de-C-terminal lysine] anti-(human CD20 antigen) (human-Mus musculus monoclonal rituximab (IDEC-C2B8) γ4-chain), (135→213′′),(135′→213′′′)-bis(disulfide) with immunoglobulin, anti-(human CD20 antigen) (human-Mus musculus monoclonal rituximab (IDEC-C2B8) κ-chain), (404→161′′′′)-disulfide with immunoglobulin [146′′′′-glutamine,161′′′′-cysteine,180′′′′-glutamine,191′′′′-glutamine] anti-(human CD3 antigen ε-chain) (human-Mus musculus monoclonal W3311-2.306.4-z1 light chain variable region) fusion protein with T cell receptor α-chain (human C-region fragment)
besnotamig [INN]
heavy chain H-gamma4 chimeric anti-MS4A1 (hole) (H) (1-447) [VH (Mus musculus IGHV1-47-27*01 (99.0%) -(IGHD) -IGHJ1*01 (87.5%) S128>A (121), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10, 14-G4v75 CH3 C5, 14-G4v33 CH3 S22, A24, V86 (hole), 10-G4v110 CHS delK2 (CH1 (122-219), hinge 1-12 S10>P (229) (220-231), CH2 L92 (310) (232-341), CH3 Y5>C (350), T22>S (367), L24>A (369), Y86>V (408) (342-446), CHS K2>del (447)) (122-447)], (135-213')-disulfide with light chain L-kappa chimeric anti-MS4A1 (L') (1'-213') [V-KAPPA (Mus musculus IGKV4-72*01 (95.8%) -IGKJ1*01 (100%), CDR-IMGT [5.3.9] (27'-31'.49'-51'.88'-96')) (1'-106') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (152'), V101 (190')) (107'-213')] heavy chain VH-G4(CH1) chimeric anti-MS4A1-10mer -VHTRBC2-G4(9h-CH2-CH3) humanized anti-CD3E (knob) (H'') (1''-720'') [VH-G4(CH1) chimeric anti-MS4A1 (1''-227'') [VH (Mus musculus IGHV1-47-27*01 (99.0%) -(IGHD) -IGHJ1*01 (87.5%) S128>A (121), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG4*01 (CH1 (122''-219'')] -10-mer bis(tetraglycyl-seryl) linker (220''-229'') -VH-TRBC2-G4(9h-CH2-CH3) humanized anti-CD3E (230''-700'') [VH (Homo sapiens IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.12] (255''-262''.280''-287''.326''-337'')) (230''-347'') -Homo sapiens TRBC2*01 (97.7%) 17-TRBC2v1 C79, Q85.6, A85.1, A125 del (C-BETA-2 S79>C (404''), N85.6>Q (417''), C85.1>A (422''), A125>del)) (348''-475'') -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10, 14-G4v74 CH3 C10, 14-G4v32 CH3 W22 (knob), 10-G4v110 CHS delK2 (hinge 4-12 S10>P (482'') (476''-484''), CH2 L92 (563'') (485''-594''), CH3 S10>C (608''), T22>W (620'') (595''-699''), CHS K2>del (700'')) (476''-700'')], (135''-213''')-disulfide with light chain L-kappa chimeric anti-MS4A1 (1'''-213''') [V-KAPPA (Mus musculus IGKV4-72*01 (95.8%) -IGKJ1*01 (100%), CDR-IMGT [5.3.9] (27'''-31'''.49'''-51'''.88'''-96''')) (1'''-106''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (152'''), V101 (190''')) (107'''-213''')], (404''-161'''')-disulfide with light chain Vkappa-TRAC humanized anti-CD3E (1''''-207'''') [V-KAPPA(Homo sapiens IGKV4-1*01 (89.9%) -IGKJ4*01 (100%), CDRIMGT [12.3.8] (27''''-38''''.56''''-58''''.95''''-102'''')) (1''''-112'''') -Homo sapiens TRAC*01 (95.6%) 17-TRACv1 Q38, C84, Q90, Q109 (C-ALPHA N38>Q (146''''), T84>C (161''''), N90>Q (180''''), N109>Q (191'''') (113''''-204'''') -CONNECTING-REGION (205''''-207'''')) (113''''-207'''')]; dimer 227-480'':230-483'':350-608'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
immunoglobulin (H-gamma4_L-kappa)_(VH-G4(CH1)(_Lkappa)-10mer-VH-TRBC2-G4(9h-CH2-CH3)_V-kappa-TRAC), anti-[Homo sapiens MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], chimeric and humanized monoclonal antibody, bispecific, trivalent
